Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives…
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
First subject dosed in Phase I study to evaluate safety and tolerability of…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
New research has discovered that the ongoing COVID-19 pandemic has triggered a…
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…
Deals agreed as Infex’s resistance bypass drug program heads for clinic
Alderley Park, Cheshire Infex Therapeutics has appointed Pharmaron to help…